Tenosynovial giant cell tumor.
Kager M, Kager R, Fałek P, Fałek A, Szczypiór G, Niemunis-Sawicka J, Rzepecka-Wejs L, Starosławska E, Burdan F.
Folia Med Cracov. 2022;62(2):93-107. doi: 10.24425/fmc.2022.141702.
Medical Management of Tenosynovial Giant Cell Tumor.
Palmerini E, Trent JC, Hornicek FJ Jr.
Curr Oncol Rep. 2025 Jul;27(7):844-855. doi: 10.1007/s11912-025-01679-x. Epub 2025 May 20.
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S.
Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6.
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD; MOTION investigators.
Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3.
MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients.
Niu X, Ravi V, Shan B, Guo Q, Shi H, Zou Q, Gelderblom H.
Future Oncol. 2026 Feb;22(5):507-514. doi: 10.1080/14796694.2024.2396227. Epub 2024 Sep 17.
Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.
Stern S, McKenzie PF, Bernthal N, O'Neill S, Palmerini E, Randall RL, Tap W, Scharschmidt T, Rothschild S.
Future Oncol. 2025 May;21(12):1501-1510. doi: 10.1080/14796694.2025.2488635. Epub 2025 Apr 8.
Tenosynovial giant cell tumor: a case report.
Ansel S, Yan X, Chong P, Lo S, McCleery M, Mahendra A, MacDuff E, Cowie F, Nixon I, White J; Scottish Sarcoma Network.
J Med Case Rep. 2023 Oct 6;17(1):419. doi: 10.1186/s13256-023-04156-w.
Treatment updates on tenosynovial giant cell tumor.
Palmerini E, Staals EL.
Curr Opin Oncol. 2022 Jul 1;34(4):322-327. doi: 10.1097/CCO.0000000000000853.
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis.
Assi T, Moussa T, Ngo C, Faron M, Verret B, Lévy A, Honoré C, Hénon C, Péchoux CL, Bahleda R, Vibert J, Cesne AL.
Cancer Treat Rev. 2025 Mar;134:102904. doi: 10.1016/j.ctrv.2025.102904. Epub 2025 Feb 20.
Tenosynovial giant cell tumor: case report and molecular investigation.
Guimarães LM, Bastos VC, Souza MRF, de Castro WH, Gomes CC, Gomez RS.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Jul;138(1):e13-e17. doi: 10.1016/j.oooo.2024.01.014. Epub 2024 Feb 2.
